Angiogenesis and ophthalmic disease

Angiogenesis

Volumn 3, Issue 1, 1999, Pages 9-14

  Adamis, Anthony P ^a,b,c   Aiello, Lloyd P ^a   D'Amato, Robert A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Angiogenesis; Choroid; Cornea; Development; Eye; Iris; Neovascularization

Indexed keywords

EID: 0000583023     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009071601454     Document Type: Review

References (69)

1. Lee P, Wang CC, Adamis AP. Ocular neovascularization: An epidemiological review. Surv Ophthalmol 1998; 43: 245-69.
2. Huang AJW, Watson BD, Hernandez E, Tseng SCG. Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization. Ophthalmology 1988; 95: 228-35.
3. Huang AJW, Watson BD, Hernandez E, Tseng SCG. Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization. Ophthalmology 1988; 95: 228-35.
4. Arentsen JJ. Corneal neovascularization in contact lens wearers. Int Ophthalmol Clin 1986; 26: 15-23.
5. Kruse FE, Chen JJY, Tsai RJF, Tseng SCG. Conjunctival transdifferentiation is due to the incomplete removal of limbal basal epithelium. Invest Ophthalmol Vis Sci 1990; 31: 1903-13.
6. Klintworth GK. Corneal Angiogenesis. A Comprehensive and Critical Review, 1st edition. New York: Springer-Verlag 1990; 26.
7. Amano S, Rohan R, Kuroki M et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998; 39: 18-22.
8. Cursifen C, Hofman-Rummelt C, Kuche MNGOH. VEGF-immunoreactivity in human corneal buttons with neovascularization. ARVO abstracts. Invest Ophthalmol Vis Sci 1998; 39: S3418.
9. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal disease. Trans Ophthalmol Soc UK 1948; 68: 137-80.
10. Ashton N. Retinal vascularization in health and disease. Am J Ophthlamol 1957; 44: 7-24.
11. Wise GN. Retinal neovascularization. Trans Am Ophthalmol Soc 1956; 54: 729-826.
12. Nork TM, Tso MO, Duvall J, Hayreh SS. Cellular mechanisms of iris neovascularization secondary to retinal vein occlusion. Arch Ophthalmol 1989; 107: 581-6.
13. Schultze RR. Rubeosis iridis. Am J Ophthalmol 1967; 63: 487-95.
14. Shima DT, Gougos A, Miller JW et al. Cloning and mRNA expression of VEGF in ischemic retinas of Maccaca fasicularis. Invest Ophthalmol Vis Sci 1996; 37: 1334-40.
15. Miller J, Adamis AP, Shima DT et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-84.
16. Adamis AP, Shima DT, Tolentino M et al. Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch Ophthalmol 1996; 114: 66-71.
17. Tolentino MJ, Miller JW, Gragoudas ES et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996; 114: 964-70.
18. Pe'er J, Shweiki D, Itin A et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72: 638-45.
19. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients wth diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-87.
20. Pournaras CJ, Tsacopoulos M, Strommer K et al. Scatter photocoagulation restores tissue hypoxia in experimental vaso-proliferative microangiopathy in miniature pigs. Ophthalmology 1990; 97: 1329-33.
21. Pournaras CJ, Miller JW, Gragoudas ES et al. Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol 1997; 115: 1553-8.
22. Imesch PD, Bindley CD, Wallow IH. Clinicopathologic correlation of intraretinal microvascular abnormalities. Retina 1997; 17: 321-9.
23. Tolentino MJ, Miller JW, Gragoudas ES et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103: 1820-8.
24. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: The second report of the diabetic retinopathy study findings. Ophthalmology 1978; 85: 82-92.
25. Federman JL, Boyer D, Lanning R, Breit P. An objective analysis of proliferative diabetic retinopathy before and after pars plana vitrectomy. Ophthalmology 1979; 86: 276-82.
26. Schroder S, Palinski, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary non-perfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139: 81-00.
27. McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 1995; 147: 642-53.
28. Miyamoto K, Ogura Y. Role of leukocytes in diabetic microcirculatory disturbances. Microvas Res 1997; 54: 43-8.
29. Braun RD, Fisher TC, Meiselman HJ, Hatchell DL. Decreased deformability of polymorphonuclear leukocytes in diabetic cats. Microcirculation 1996; 3: 271-8.
30. Kelly LW, Barden CA, Tiedeman JS, Hatchell DL. Alterations in viscosity and filterability of whole blood and blood cell subpopulations in diabetic cats. Exp Eye Res 1993; 56: 341-7.
31. Dobbie JG, Kwaan HC, Colwell J, Suwanwela N. Role of platelets in pathogenesis of diabetic retinopathy. Arch Ophthalmol 1974; 91: 107-9.
32. Diacovo TG, Puri KD, Warnock RA et al. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996; 273: 252-5.
33. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
34. Aiello LP, Northrup JM, Keyt BA et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Archives of Ophthalmology 1995; 113: 1538-44.
35. Takagi H, King GL, Robinson GS et al. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Opthalmol Vis Sci 1996; 37: 2165-76.
36. Xia P, Aiello LP, Ishii H et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98: 2018-26.
37. Thieme H, Aiello LP, Takagi H et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 1995; 44: 98-103.
38. Okamoto N, Tobe T, Hacket SF et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina. A new model of intraretinal and subretinal neovascularization. Am J Pathol 1997; 151: 281-91.
39. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sec USA 1995; 92: 10457-61.
40. Takagi H, King GL, Aiello LP. Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 1996; 45: 1016-23.
41. Adamis AP, Miller J, Bernal M-T et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
42. Shima D, Adamis AP, Ferrara N et al. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995; 2: 182-93.
43. Malecaze F, Clamens S, Simorre-Pinatel V et al. Detection of vascular endothelial growth factor messanger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112: 1476-82.
44. Hata Y, Duh E, Zhang K et al. Transcriptoin factors sp1 and sp3 affect vascular endothelial growth factor receptor KDR expression through a novel recognition sequence. J Biol Chem 1998; 273: 19294-303.
45. Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-31.
46. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularizatoin caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171-9.
47. Aiello LP, Bursell SE, Clermont A et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80.
48. Hammes H-P, Brownlee M, Jonczyk A et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 1996; 2: 529-33.
49. Luna J, Tobe T, Mousa SA et al. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab Invest 1998; 75: 563-73.
50. Friedlander M, Brooks PC, Shaffer RW et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-2.
51. Smith LE, Kopchick JJ, Chen W et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276: 1706-9.
52. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration of choroidal neovascularization. Am J Ophthalmol 1993; 115: 786-91.
53. Group MPS. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 1990; 108: 825-31.
54. Sarks SH. Ageing and degeneration in the macular region: A clinico-pathological study. Br J Ophthalmol 1976; 60: 324-41.
55. Chen JC, Fitzke FW, Pauleikhoff D, Bird AC. Functional loss in age-related Bruch's membrane change with choroidal perfusion defect. Invest Ophthalmol Vis Sci 1992; 33: 334-40.
56. Green WR, Enger C. Age-related macular degeneration histopathological studies. Ophthalmology 1992; 100: 1519-35.
57. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. [Review]. Surv Ophthalmol 1988; 32: 375-413.
58. Allikmets R, Shroyer NF, Singh N et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science 1997; 277: 1805-7.
59. Lopez PF, Sippy BD, Lambert HM et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37: 855-68.
60. Ishibashi T, Hata Y, Yoshikawa H et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997; 235: 159-67.
61. Friedlander M, Brooks PC, Shaffer RW et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-2.
62. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-42.
63. Stone J, Itin A, Alon T et al. Development of retinal vasculature is mediated by hypoxia- induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15: 4738-47.
64. Zhang Y, Stone J. Role of astrocytes in the control of developing retinal vessels. Invest Ophthalmol Vis Sci 1997; 38: 1653-66.
65. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-8.
66. Alon T, Hemo I, Itin A et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med 1995; 1: 1024-8.
67. Benjamin LE, Golijanin D, Itin A et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-65.
68. Williamson JR, Chang K, LeJeune W et al. Links between retinal vascular dysfunction induced by elevated glucose levels and VEGF. ARVO abstracts. Invest Ophthalmol Vis Sci 1996; 37: S47.
69. Miyamoto K, Ogura Y, Hamada M et al. In vivo quantification of leukocyte behavior in the retina during endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1996; 37: 2708-15.